QRS interval widening appears to be highly specific for the diagnosis of hyperkalemia in patients with end-stage kidney disease. ECG changes, in general, have poor sensitivities for hyperkalemia in ...

AliveCor has received approval from the Food and Drug Administration (FDA) to develop a non-invasive method of detecting high blood potassium levels. The startup, which chiefly focuses on monitoring ...

In patients with severe hyperkalemia, the Brugada syndrome ECG phenotype is associated with a high prevalence of malignant arrhythmias and all-cause mortality. Among patients with severe hyperkalemia ...

Although serum potassium monitoring is recommended to reduce the risk of hyperkalemia, only a small percentage of patients taking RAAS inhibitors are monitored. Hyperkalemia diagnosis is often missed ...

AccurKardia, an innovator in ECG-based diagnostics technology, has announced the initiation of a multicenter clinical pilot of AK+ GuardTM, an FDA Breakthrough Device Designated AI-powered technology ...

Over the weekend AliveCor announced that its technology was validated in two studies. The first found that its KardiaBand, which works as a personal electrocardiogram device, can accurately detect ...

An AliveCor algorithm has identified people with high potassium levels from electrocardiogram (ECG) data. Limited prospective clinical testing suggests pairing the algorithm with AliveCor’s smartphone ...

A new study has added momentum to a commercialization push for a Mayo Clinic-backed wearable device and smartphone app which analyzes user-generated electrocardiograms to detect high blood potassium ...

The treatment of hyperkalemia can require urgent measures. Fortunately, it can usually be preemptively managed before serum K+ values become dangerously high. The urgency with which therapy is ...